Summary
Sparsomycin (Sm) is a known inhibitor of ribosomal protein synthesis with an attractive anticancer potential. Recently, several analogues of Sm which are more active than the parent drug were selected for further study on the basis of in vitro investigations. Six analogues as well as the parent drug were tested for their antitumor activity in eight in vivo murine tumor models: P388 and L1210 leukemias, RC renal cell carcinoma, B16 melanoma, C38 colon carcinoma, LL Lewis lung carcinoma, C22LR osteosarcoma and M5076 sarcoma. Sm itself appeared to have only borderline activity on L1210 leukemia. The analogues that were most active in vitro showed also the highest in vivo activity. The most sensitive tumors were RC, L1210 and P388. Minimal activity was found on B16 and no activity on C22LR, M5076, C38 and LL. The most active compounds are deshydroxy-Sm, ethyl-deshydroxy-Sm and n-pentyl-Sm. There was a considerable loss of activity when L1210 leukemia was implanted sc while the drugs were administered iv. Only one drug, ethyl-deshydroxy-Sm appeared to be active in this assay. No single most effective compound could be found in this study. The overall activity of Sm and its analogues is moderate. The three analogues which show high activity in three ascitic tumors will be further investigated using human tumor xenograft models.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Monro RE, Celma ML, Vazquez D: Action of sparsomycin on ribosome-catalyzed peptidyl transfer. Nature 222:356–358, 1969
Argoudelis AD, Herr RR: Sparsomycin, a new antitumor antibiotic. II. Isolation and characterization. Antimicrob Agents Chemother 780–786, 1962
Owen SP, Dietz A, Camiener GW: Sparsomycin, a new antitumor antibiotic. I. Discovery and biological properties. Antimicrob Agents Chemother 772–779, 1962
Close HP, McFarlane JR: Ocular toxicity with sparsomycin (NSC 59729) in a phase I study: a preliminary report. Cancer Chemother Rep 43:29–31, 1964
National Institute of Health. Developmental Therapeutics Program. Division of Cancer Treatment. Screening data summary on sparsomycin (NSC 059729), Bethesda, MD, National Cancer Institute, 1985
Ottenheijm HCJ, Liskamp RMJ, Van Nispen SP, Boots HA, Tyhuis MW: Total synthesis of the antibiotic sparsomycin, a modified amino-acid monoxodithioacetal. J Org Chem 46:3273–3283, 1981
Liskamp RMJ, Colstee JH, Ottenheijm HCJ, Lelieveld P, Akkerman W: Structure-activity relationships of sparsomycin and its analogues. Octylsparsomycin: the first analogue more active than sparsomycin. J Med Chem 27:301–306, 1984
Van den Broek LAGM, Liskamp RMJ, Colstee JH, Lelieveld P, Remacha M, Vazquez D, Ballesta JPG, Ottenheijm HCJ: Structure activity relationships of sparsomycin and its analogues. Inhibition of peptide bond formation in cell-free systems, and of L1210- and bacterial cell growth. J Med Chem 30:325–333, 1987
Ottenheijm HCJ: SAR of antitumor agents: endeavours involving sparsomycin. In: Harms AF (ed). Innovative Approaches in Drug Research. Elsevier Science Publishers, Amsterdam, 1986, pp 425–435
Ottenheijm HCJ, Van den Broek LAGM, Ballesta JPG, Zylicz Z: Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces. In: Ellis GP, West GB (eds) Progress of Medicinal Chemistry, Vol 23, Elsevier, Amsterdam, 1986, pp 219–268
Zylicz Z, Wagener DJT, van Rennes H, Wessels JMC, Van der Kleijn E, de Grip WJ, Ottenheijm HCJ, van den Broek LAGM, Ottenheijm HCJ: In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis. J Natl Cancer Inst 78:701–705, 1987
Zylicz Z, Wagener DJT, Van Rennes H, Wessels JMC, Van der Kleijn E, De Grip WJ, Van den Broek LAGM: In vivo potentiation of cis-diamminedichloroplatinum antitumor activity by pretreatment with sparsomycin. Cancer Lett 32:53–59, 1986
Winograd B, Oosterbaan MJM, Van der Kleijn E, Liskamp RMJ, Ottenheijm HCJ, Wagener DJT: Determination of sparsomycin in plasma and urine of the dog by means of reversed-phase high-performance liquid chromatography and first pharmacokinetic results. J Chromatogr (Biomed Appl) 275:145–153, 1983
Weil CS: Tables for convenient calculation of median-effective dose (LD50 or ED50) and instructions in their use. Biometrics 7:249–263, 1952
Lelieveld P, Mulder JH: Three tumor sensitivity tests evaluated with mouse tumors. Int J Cell Cloning 5:335–346, 1987
Vandendris M, Dumont P, Heimann R, Atassi G: Development and characterization of a new murine renal tumor model. Cancer Chemother Pharmacol 11:182–187, 1983
Author information
Authors and Affiliations
Additional information
Part of this work was presented in the 5th EORTC/NCI symposium on New Drugs in Cancer Therapy, Amsterdam, 22–24 October 1986.
Rights and permissions
About this article
Cite this article
Zylicz, Z., Wagener, D.J.T., van Rennes, H. et al. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models. Invest New Drugs 6, 285–292 (1988). https://doi.org/10.1007/BF00173646
Issue Date:
DOI: https://doi.org/10.1007/BF00173646